Abstract
Epidemiological data [1] indicate that postmenopausal estrogen replacement therapy (ERT) may be associated with a reduced risk of Alzheimer’s disease (AD) and ERT may also improve the cognitive performance of AD affected women. Moreover epidemiological data [2] suggest a sex difference in the prevalence of AD. The decline in sex steroid levels during aging has been widely studied; the receptor distribution in brain mirrors the distribution of the neuropathological markers of AD, therefore it is possible that estrogen levels decay in postmenopause contributes to the exacerbation of molecular events taking place with aging, thus leading to the development of AD.
Keywords
- Amyloid Precursor Protein
- Estrogen Replacement Therapy
- Nerve Growth Factor Receptor
- DEMENTING Illness
- Amyloid Precursor Protein Metabolism
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Tang M, Jacobs D, Stern Y, et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348:429–32.
Fratiglioni L, Viitanen M, Vonstrauss E, et al. Very old women at highest risk of dementia and AD — incidence data from the Kungsholmen project, Stockholm, Neurology 1997;48: 132–38.
Gasparini L, Racchi M, Binetti G, et al. Peripheral markers in testing pathophysiological hypotheses and diagnosing AD. FASEB J 1998;12:17–34.
Govoni S, Trabucchi M, Racchi M, Biological basis for the pharmacological modulation of APP metabolism. In: Brunello N, et al. (editors). Mental disorders in the elderly: New therapeutic approaches. Berlin: Karger, 1998: 84–90.
Sohrabji F, Miranda RC, Toran-Allerand CD. Estrogen differentially regulates estrogen and nerve growth factor receptor mRNAs in adult sensory neurons. J Neurosci 1994;14:459–71.
Toran-Allerand CD, Miranda RC, Bentham WDL, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci USA 1992;89:4668–72.
Keller JN, Germeyer A, Begley JG, Mattson MP. 17β-estradiol attenuates oxidative impairment of synaptic Na+K+-ATPase activity, glucose transport, and glutamate transport induced by amyloid-peptide and iron. J Neurosci Res 1997;50:522–30.
Jaffe AB, Toran-Allerand CD, Greengard P, Gandy SE. Estrogen regulates metabolism of APP. J Biol Chem 1994;269:13065–68.
Xu H, Gouras GK, Greenfield JP, et al. Estrogen reduces neuronal generation of Alzheimer β-amyloid peptides. Nature Med 1998;4:447–51.
Ianna P, Racchi M, Cattaneo E, et al. Estrogen effect on brain biology and cognition. In: Paoletti R, et al (editors). Women’s health and menopause. Dordrecht: Kluwer Academic Publisher, 1997: 191–98.
Gasparini L, Racchi M, Benussi L, et al. Effect of energy shortage and oxidative stress on APP metabolism in cos cells. Neurosci Lett 1997;23:113–17.
Srivastava RAK, Bhasin N, Srivastava N. ApoE gene expression in various tissues of mouse and regulation by estrogen. Biochem Mol Biol Intern 1996;38:91–101.
Bellosta S, Nathan BP, Orth M, et al. Stable expression and secretion of apo E3 and E4 in mouse neuroblastoma cells. J Biol Chem 1995;270:27063–61.
Brandi L, Becherini L, Gennari L, et al. Association of the estrogen receptor gene polymorphisms with sporadic AD. Neurobiol Aging 1998;19(Supp.1):124.
Gennari L, Becherini L, Masi L, et al. Vitamin D and estrogen receptor allelic variants in Italian postmenopausal women: Evidence of multiple gene contribution to bone mineral density. J Clin Endocrinol Metab 1998;83:938–44.
Johansson C, Skogg L. A population based study on the association between dementia and hip fractures in 85 year olds. Aging Clin & Expt Res 1996;8:189–96.
Meier-Ruge W, Bertoni-Freddari C, Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of AD. Gerontology 1994;40:246–52.
Manning CA, Ragozzino ME, Gold PE. Glucose enhancement of memory in patients with probable SDAT. Neurobiol Aging 1993;14:523–28.
Solerte SB, Cerutti N, Fioravanti M, et al. Alterations of 24-h serum insulin profile in patients with SDAT: Potential link with the cognitive derangement. Aging Clin Exp Res 1997;9(Suppl.4):85.
Rights and permissions
Copyright information
© 1999 Kluwer Academic Publishers and Fondazione Giovanni Lorenzini
About this chapter
Cite this chapter
Govoni, S., Solano, D., Solerte, B.S., Guaita, A., Racchi, M. (1999). Role of Estrogens in Dementing Illnesses: Hypotheses on the Biological Rationale. In: Women’s Health and Menopause. Medical Science Symposia Series, vol 13. Springer, Dordrecht. https://doi.org/10.1007/978-0-585-37973-9_22
Download citation
DOI: https://doi.org/10.1007/978-0-585-37973-9_22
Publisher Name: Springer, Dordrecht
Print ISBN: 978-0-7923-5906-7
Online ISBN: 978-0-585-37973-9
eBook Packages: Springer Book Archive